ACADIA Pharmaceuticals

US · ACAD #2404 by market cap Listed 1970

19.65 -0.09 -0.46%

Live - 5344 symbols - heartbeat 554s ago · 2026-10-08 07:15

Pre-market 19.80 +0.75%

After-hours 19.70 +0.25%

Market cap: 3.39B
P/E (TTM): 8.81
P/B: 2.59
EPS: 2.30
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on ACAD?

Anonymous reader poll. Unscientific, not investment advice.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Founded: 1993
CEO: Ms. Catherine Owen Adams
Employees: 798
Headquarters: San Diego, California, United States of America
Fiscal year end: 12-31
Website: acadia.com

Company profile

Exchange: US
Symbol: ACAD
Market-cap rank: #2404
Listing date: 1970-01-01
Market cap: 3.39B
Float cap: 2.52B
Shares out: 172.31M
Float shares: 128.35M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:15:07 · For reference only, not investment advice and not tailored to your situation.